|Bid||429.40 x N/A|
|Ask||436.80 x N/A|
|Day's range||436.00 - 436.00|
|52-week range||412.00 - 504.60|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||03 Jul 2019|
|1y target est||N/A|
Eurofins U.S. Clinical Diagnostics announced the launch date of its pooled PCR test to detect SARS-CoV-2 and significantly reduce the price per PCR test for clients. Pooling tests, historically used in blood banks, can now be used by the myriad of industries seeking a highly accurate and cost-effective means to conduct COVID-19 testing. Those industries include corporations, sports organizations, educational institutions, congregate care/nursing, and manufacturing.
Eurofins Technologies (Paris:ERF) announces the launch of reagents for automated isolation of high-quality SARS-CoV-2 RNA (ribonucleic acid) from viral particles of human respiratory specimens. The reagents’ magnetic bead-based, automated method extracts and isolates virus particles and their respective RNA on many open platforms for subsequent real-time RT-PCR (reverse transcription polymerase chain reaction) analysis using approved IVD kits.
A study undertaken by Eurofins scientists has resulted in a robust method to analyse SARS-CoV-2 in wastewater samples, allowing for early detection of virus presence at a given site, before the virus spreads too broadly or as a way to monitor the effectiveness of containment measures put in place. https://www.medrxiv.org/content/10.1101/2020.07.10.20150573v1